Jade Biosciences (NASDAQ:JBIO) Sees Large Volume Increase Following Analyst Upgrade

Jade Biosciences, Inc. (NASDAQ:JBIO) saw unusually-strong trading volume on Monday after HC Wainwright raised their price target on the stock from $45.00 to $55.00. HC Wainwright currently has a buy rating on the stock. Approximately 374,719 shares traded hands during trading, a decline of 19% from the previous session’s volume of 463,605 shares.The stock last traded at $17.6480 and had previously closed at $21.04.

Several other equities research analysts have also commented on JBIO. Wedbush boosted their price target on Jade Biosciences from $24.00 to $34.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Stifel Nicolaus set a $40.00 price target on Jade Biosciences in a research note on Friday, March 6th. Lifesci Capital raised Jade Biosciences to a “strong-buy” rating in a research note on Friday, March 6th. Guggenheim boosted their price target on Jade Biosciences from $23.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Weiss Ratings lowered Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of JBIO. JPMorgan Chase & Co. acquired a new position in shares of Jade Biosciences during the 2nd quarter worth approximately $154,000. Legal & General Group Plc acquired a new position in Jade Biosciences in the 2nd quarter valued at $29,000. Rhumbline Advisers acquired a new position in Jade Biosciences in the 2nd quarter valued at $445,000. Russell Investments Group Ltd. acquired a new position in Jade Biosciences in the 2nd quarter valued at $31,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Jade Biosciences in the 2nd quarter valued at $114,000.

Jade Biosciences Stock Performance

The company has a fifty day simple moving average of $20.47 and a two-hundred day simple moving average of $16.44. The company has a market capitalization of $903.93 million, a price-to-earnings ratio of -9.13 and a beta of 1.45.

Jade Biosciences (NASDAQ:JBIO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.05). As a group, analysts expect that Jade Biosciences, Inc. will post -2.43 EPS for the current year.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.